Key result
Propofol significantly inhibited platelet aggregation both in vivo and in vitro, an effect caused by the drug itself rather than its fat emulsion solvent, without prolonging bleeding time.
Why the study?
Does propofol inhibit platelet aggregation in patients compared to its fat emulsion solvent?
Population
10 patients receiving intravenous infusion of propofol and 10 healthy volunteers
Comparison
Intravenous infusion of propofol and various… vs Intralipos infused in healthy volunteers and…
Design
Other
Authors
Loading...
Reassures on hemostasis safety despite aggregation effects; leaves open clinical bleeding relevance in patients.
Does propofol inhibit platelet aggregation in patients compared to its fat emulsion solvent?
Propofol inhibits platelet aggregation through suppressed calcium influx and discharge, without clinically impairing hemostasis.
Aoki et al. (1998) studied this question. Propofol vs. Intralipos was evaluated on Platelet aggregation. Propofol significantly inhibited platelet aggregation both in vivo and in vitro, an effect caused by the drug itself rather than its fat emulsion solvent, without prolonging bleeding time.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: